Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (NYSE: HLN) covers the month of August 2026, with specific data as of July 31, 2026. Haleon is a consumer health company focused on everyday health across six categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company markets trusted brands including Advil, Centrum, Panadol, Sensodyne, and Voltaren.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a capital disclosure rather than a financial results statement.
Material Changes and Capital Structure
The primary disclosure concerns the company's share capital as of July 31, 2026:
- Total Issued Shares: 8,820,906,422 ordinary shares of £0.01 each.
- Treasury Shares: 11,879,800 shares held in treasury.
- Voting Rights: 8,809,026,622 ordinary shares carry voting rights.
This voting share count serves as the denominator for shareholders calculating notification obligations under the FCA's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document focuses solely on capital structure and corporate governance notifications.
Investor Verification Checklist
- Verify the total number of voting shares (8,809,026,622) for compliance with disclosure thresholds.
- Confirm the number of treasury shares (11,879,800) held by the company.
- Check the company secretary contact (company.secretary@haleon.com) for submitting notifiable interests.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and earnings.